Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
81 | Publisher: Grand View Research
Industry: Biotechnology | Report Format: Electronic (PDF)
Global circulating tumor cells market is expected to reach USD 2.28 billion by 2020. Growing prevalence of cancer has heightened the need for effective and early diagnosis. Circulating tumor cells cater to this heightened need and are therefore, expected to witness a surge in demand during the forecast period. Majority of cancer deaths are due to circulating tumor cells and an early diagnosis of the same is expected to increase survival rates. Targeted therapy in cancer has large untapped opportunities and therefore, entails extensive R&D investments aimed at new product development. However, high procedure costs and lack of commercialized products are expected to impede market growth during the forecast period.
Further key findings from the study suggest:
Tumor cell detection was the leading product segment in 2013 primarily owing to the advantages associated with therapeutic monitoring and high procedure prices. Its market is expected to reach an estimated value of over USD 250.0 million by 2020.
Molecular technique emerged as the largest tumor cell detection segment in 2013. This technique holds several advantages over optical tumor cell detection technique and therefore, witnesses higher usage rates. Notable advantages of molecular tumor cell detection techniques include higher sensitivity and high-throughput analysis. Moreover, the introduction of new products such as CellSearch by Janssen Pharmaceutical is expected to drive segment growth.
Tumor cell enrichment is also expected to witness lucrative growth over the next six years. The market is primarily driven by rapidly growing demand for prognostic technologies coupled with the presence of high patient unmet needs.
Immunological and immunomagnetic techniques associated with tumor cell enrichment were the largest market in 2013, accounting for a share of over 50.0%. It is the most commonly used diagnostic technique and therefore, hold high market penetration rates.
North America was the most revenue generating market in 2013. Presence of sophisticated healthcare infrastructure, growing prevalence of cancer and relatively larger presence of commercialized products are some factors attributing to its market position.
The Asia Pacific circulating tumor cells market holds lucrative future growth opportunities. High prevalence of unmet patient needs, constantly improving healthcare infrastructure and increasing healthcare expenditure levels in the emerging markets of India and China are some factors accounting for its market attractiveness.
Some key players of the circulating tumor cells market include AVIVA BioSciences Corporation, Silicon Biosystems S.p.A, Advanced Cell Diagnostics Inc, Celula Inc., Epic Sciences Inc., AdnaGen AG, Vitatex Inc, Rarecells Inc. and Fluxion Biosciences Inc.
For the purpose of this study, Grand View Research has segmented the global circulating tumor cells market on the basis of technology, application and region:
Global Circulating Tumor Cells Technology Outlook (Revenue, USD Million, 2012 - 2020)
Tumor Cell Enrichment
Filtration
Centrifugation
Immunological and Immunomagnetic
Tumor Cell Detection
Molecular
Optical
Global Circulating Tumor Cells Application Outlook (Revenue, USD Million, 2012 - 2020)
Prostate Cancer
Breast Cancer
Colorectal Cancer
Others (pancreatic, lung, ovarian cancer)
Circulating Tumor Cells Regional Outlook (Revenue, USD Million, 2012 - 2020)
North America
U.S.
Canada
Europe
France
Germany
Spain
Asia Pacific
India
China
Japan
RoW
Table of Contents
Chapter 1. Executive Summary 1.1. Circulating Tumor Cells - Industry Summary and Critical Success Factors (CSFs) Chapter 2. Circulating Tumor Cells Industry Outlook 2.1. Market Segmentation 2.2. Market Size and Growth Prospects 2.3. Circulating Tumor Cells Market Dynamics 2.3.1. Market Driver Analysis 2.3.2. Market Restraint Analysis 2.4. Key Opportunities Prioritized 2.5. Industry Analysis - Porter's 2.6. Circulating Tumor Cells Market PESTEL Analysis, 2013 Chapter 3. Circulating Tumor Cells Technology Outlook 3.1. Market Estimates and Forecasts, 2012 - 2020 (USD Million) 3.2. Tumor Cell Enrichment Technology 3.2.1. Market Estimates and Forecasts, 2012 - 2020 (USD Million) 3.2.2.Filtration Market Estimates and Forecasts, 2012 - 2020 (USD Million) 3.2.3.Centrifugation Market Estimates and Forecasts, 2012 - 2020 (USD Million) 3.2.4.Immunological and Immunomagnetic Market Estimates and Forecasts, 2012 - 2020 (USD Million) 3.3. Tumor Cell Detection Technology 3.3.1.Market Estimates and Forecasts, 2012 - 2020 (USD Million) 3.3.2. Molecular Market Estimates and Forecasts, 2012 - 2020 (USD Million) 3.3.3.Optical Market Estimates and Forecasts, 2012 - 2020 (USD Million) Chapter 4. Circulating Tumor Cells Application Outlook 4.1. Market Estimates and Forecast By Application, 2012 - 2020 (USD Million) 4.2. Prostate Cancer 4.2.1.Market Estimates and Forecasts, 2012 - 2020 (USD Million) 4.3. Breast Cancer 4.3.1.Market Estimates and Forecasts, 2012 - 2020 (USD Million) 4.4. Colorectal Cancer 4.4.1.Market Estimates and Forecasts, 2012 - 2020 (USD Million) 4.5. Others 4.5.1.Market Estimates and Forecasts, 2012 - 2020 (USD Million) Chapter 5. Circulating Tumor Cells Regional Outlook 5.1. North America 5.1.1.Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million) 5.1.2.U.S. Market Estimates and Forecast, by Technology, 2012 - 2020 (USD Million) 5.1.3.Canada Market Estimates and Forecasts, by Technology, 2012-2020 (USD Million) 5.1.4.Market Estimates and Forecast, by Application, 2012 - 2020 (USD Million) 5.1.5.U.S. Market Estimates and Forecast, by Application, 2012 - 2020 (USD Million) 5.1.6.Canada Market Estimates and Forecast, by Application, 2012 - 2020 (USD Million) 5.2. Europe 5.2.1.Europe Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million) 5.2.2.France Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million) 5.2.3.Spain Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million) 5.2.4.Germany Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million) 5.2.5. Europe Market Estimates and Forecasts, by Application, 2012 - 2020 (USD Million) 5.2.6.France Market Estimates and Forecasts, by Application, 2012 - 2020 (USD Million) 5.2.7.Spain Market Estimates and Forecasts, by Application, 2012 - 2020 (USD Million) 5.2.8.Germany Market Estimates and Forecasts, by Application, 2012 - 2020 (USD Million) 5.3. Asia Pacific 5.3.1.Asia Pacific Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million) 5.3.2.India Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million) 5.3.3.China Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million) 5.3.4.Japan Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million) 5.3.5.Asia Pacific Market Estimates and Forecasts, by Application, 2012 - 2020 (USD Million) 5.3.6.India Market Estimates and Forecasts, by Application, 2012 - 2020 (USD Million) 5.3.7.China Market Estimates and Forecasts, by Application, 2012-2020 (USD Million) 5.3.8.Japan Market Estimates and Forecasts, by Application, 2012-2020 (USD Million) 5.4. RoW 5.4.1.RoW Market Estimates and Forecasts, by Technology, 2012- 2020 (USD Million) 5.4.2.RoW Market Estimates and Forecasts, by Application, 2012 - 2020 (USD Million) Chapter 6. Competitive Landscape 6.1 AVIVA BioSciences Corporation 6.1.1 Company Overview 6.1.2 Financial Performance 6.1.3 Product Benchmarking 6.1.4 Strategic Initiatives 6.2 AdnaGen AG 6.2.1 Company Overview 6.2.2 Financial Performance 6.2.3 Product Benchmarking 6.2.4 Strategic Initiatives 6.3 Celula Inc 6.3.1 Company Overview 6.3.2 Financial Performance 6.3.3 Product Benchmarking 6.3.4 Strategic Initiatives 6.4 Advanced Cell Diagnostics Inc. 6.4.1 Company Overview 6.4.2 Financial Performance 6.4.3 Product Benchmarking 6.4.4 Strategic Initiatives 6.5 Epic Sciences Inc. 6.5.1 Company Overview 6.5.2 Financial Performance 6.5.3 Product Benchmarking 6.5.4 Strategic Initiatives 6.6 Rarecells Inc. 6.6.1 Company Overview 6.6.2 Financial Performance 6.6.3 Product Benchmarking 6.6.4 Strategic Initiatives 6.7 Fluxion Biosciences Inc 6.7.1 Company Overview 6.7.2 Financial Performance 6.7.3 Product Benchmarking 6.7.4 Strategic Initiatives 6.8 Silicon Biosystems S.p.A 6.8.1 Company Overview 6.8.2 Financial Performance 6.8.3 Product Benchmarking 6.8.4 Strategic Initiatives 6.9 Vitatex Inc 6.9.1 Company Overview 6.9.2 Financial Performance 6.9.3 Product Benchmarking 6.9.4 Strategic Initiatives Chapter 7. Methodology and Scope 7.1. Research Methodology 7.2. Research Scope & Assumption 7.3. List of Data Sources List of Tables
1. Circulating Tumor Cells - Industry Summary &Critical Success Factors (CSFs) 2. Global Circulating Tumor Cells Revenue, 2012 - 2020 3. Global Circulating Tumor Cells Market Revenue By Region, (USD million), 2012 - 2020 4. Global Circulating Tumor Cells Market Revenue by Technology, (USD million), 2012 - 2020 5. Global Tumor Cell Enrichment Technology Market, 2012 to 2020 (USD million) 6. Global Filtration Market, 2012 to 2020 (USD million) 7. Global Centrifugation Market 2012 to 2020 (USD million) 8. Global Immunological and Immunomagnetic Market 2012 to 2020 (USD million) 9. Global Tumor Cell Enrichment Market, 2012 to 2020 (USD million) 10. Global Molecular Market, 2012 to 2020 (USD million) 11. Global Optical Devices Market, 2012 to 2020 (USD million) 12. Global Circulating Tumor Cells Market Revenue by Application, (USD million), 2012 - 2020 13. Global Prostate Cancer Market, 2012 to 2020 (USD million) 14. Global Breast Cancer Market, 2012 to 2013 (USD million) 15. Global Colorectal Cancer Market, 2012 to 2013 (USD million) 16. Global Other Cancer Market, 2012 to 2013 (USD million) 17. Global Circulating Tumor Cells Market, By Region, 2012 to 2020 (USD million) 18. North America Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020 19. U.S. Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020 20. Canada Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020 21. Europe Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020 22. Germany Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020 23. France Circulating Tumor Cells demand, by Technology , (USD million), 2012 - 2020 24. Spain Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020 25. Asia Pacific Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020 26. India Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020 27. Japan Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020 28. China Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020 29. RoW Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020 30. Brazil Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020 31. North America Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020 32. U.S. Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020 33. Canada Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020 34. Europe Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020 35. Germany Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020 36. France Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020 37. Spain Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020 38. Asia Pacific Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020 39. India Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020 40. Japan Circulating Tumor Cells demand, by Application,(USD million), 2012 - 2020 41. China Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020 42. RoW Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020 43. Brazil Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020 44. Global Circulating Tumor Cells Market - Competitive Landscape List of Figures 1. Circulating Tumor Cells Market Segmentation 2. Global Circulating Tumor Cells Market Revenue, 2012 - 2020 3. Circulating Tumor Cells Market Dynamics 4. Circulating Tumor Cells Company Market Share Analysis, 2012 5. Key Opportunities Prioritized 6. Industry Analysis - Porter's 7. Circulating Tumor Cells PESTEL Analysis, 2012 8. Global Circulating Tumor Cells Market, by Technology, (USD million), 2012 - 2020 9. Global Tumor Cell Enrichment Market, by region 2012 to 2020 (USD million) 10. Filtration Market, by Region, (USD million), 2012 - 2020 11. Centrifugation Market, by Region, (USD million), 2012 - 2020 12. Immunological and Immunomagnetic Market, by Region, (USD million), 2012 - 2020 13. Global Circulating Tumor Cells Market, by Application, (USD million), 2012 - 2020 14. Prostate Cancer Market, by Region, (USD million), 2012 - 2020 15. Breast Cancer Market, by Region, (USD million), 2012 - 2020 16. Colorectal Cancer Market, by Region 2012 to 2020 (USD million) 17. Other Cancer Market, by Region 2012 to 2020 (USD million) 18. Circulating Tumor Cells Market - Company Market Share Analysis, 2013 (%)
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
